Blocking of Efflux Transporters in Rats Improves Translational Validation of Brain Radioligands

Vladimir Shalgunov
Department of Drug Design and Pharmacology, University of Copenhagen
https://orcid.org/0000-0001-8956-1207

Mengfei Xiong
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Elina T L'Estrade
Department of Drug Design and Pharmacology, University of Copenhagen

Nakul R Raval
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Ida Vang Andersen
Department of Drug Design and Pharmacology, University of Copenhagen

Fraser G Edgar
Department of Drug Design and Pharmacology, University of Copenhagen

Nikolaj Raahauge Speth
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Simone Larsen Bærentzen
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Hanne Demant Hansen
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Lene Lundgaard Donovan
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Arafat Nasser
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Siv Thorlund Peitersen
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Andreas Kjær
Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet

Gitte Moos Knudsen
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen

Stina Syvänen
Department of Public Health and Caring Sciences/Geriatrics, Uppsala University

Mikael Palner
Neurobiology Research Unit and CIMBI, Rigshospitalet and University of Copenhagen
Matthias Manfred Herth (mailto:matthias.herth@sund.ku.dk)
University of Copenhagen

Original research

Keywords: P-gp, efflux transporter, PET, rodents, pigs, rats, translation

DOI: https://doi.org/10.21203/rs.3.rs-49266/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Positron Emission Tomography (PET) is a molecular imaging technique that can be used to investigate the *in vivo* pharmacology of drugs. Initial preclinical evaluation of PET tracers is often conducted in rodents due to the accessibility of disease models as well as economic considerations. Compared to larger species, rodents display a higher expression and/or activity of efflux transporters such as the P-glycoprotein (P-gp). Low brain uptake could, therefore, be species-specific and uptake in rodents not be predictive for that in humans. We hypothesized that a better prediction from rodent data could be achieved when a tracer is evaluated under P-gp inhibition. Consequently, we compared the performance of eight neuroreceptor tracers in rats with and without P-gp inhibition including a specific binding blockade. This data set was then used to predict the binding of these eight tracers in pigs.

**Methods:** PET tracers targeting serotonin 5-HT$_{2A}$ receptors ([$^{18}$F]MH.MZ, [$^{18}$F]Altanserin, [$^{11}$C]Cimbi-36, [$^{11}$C]Pimavanserin), serotonin 5-HT$_{7}$ receptors ([$^{11}$C]Cimbi-701, [$^{11}$C]Cimbi-717 and [$^{11}$C]BA-10) and dopamine D$_{2/3}$ receptors ([$^{18}$F]Fallypride) were used in the study. The brain uptake and target-specific binding of these PET radiotracers were evaluated in rats with and without inhibition of P-gp. Rat data were subsequently compared to the results obtained in pigs.

**Results:** Without P-gp inhibition, the amount of target-specific binding in the rat brain was sufficient to justify further translation for three out of eight evaluated tracers. With P-gp inhibition, five out of eight tracers justified further translation. The performance in pigs could correctly be predicted for six out of eight tracers when rat data obtained under P-gp inhibition were used, compared to four out of eight tracers without P-gp inhibition.

**Conclusions:** P-gp strongly affects the uptake of PET tracers in rodents, but false prediction outcomes can be reduced by evaluating a tracer under P-gp inhibition.

**Background**

Positron emission tomography (PET) is a powerful molecular imaging technique that has earned an established position in the clinic as a diagnostic tool. It provides a combination of high sensitivity, tissue penetration and quantitativity that is unmatched by any other molecular imaging technique [1]. Apart from its clinical applications, PET is also frequently applied in translational research and drug development to non-invasively quantify biological targets, dose-occupancy relationships or therapeutic response [2,3].

During preclinical development of novel PET tracers, it is important to use animals that represent human physiology as closely as possible. Rodents are usually tested first, for a number of reasons including lower costs compared to larger animals and the availability of disease models [4]. Compared to other species, rodents have been demonstrated to have increased brain expression of the efflux transporter, P-glycoprotein (P-gp), both in absolute terms and relative to other drug efflux transporters [5,6]. P-gp is an
ATP-dependent efflux pump, localized at the luminal side of the brain capillary endothelium which forms the blood-brain barrier (BBB). Substrates of P-gp are pumped out into the lumen of the brain capillaries and thus removed from the brain tissue [7]. P-gp activity is known to be a major factor limiting the brain uptake of PET tracers in rodents [8,9]. If tracers for central nervous system (CNS) targets are initially evaluated in rodents and show low brain uptake, they could be de-selected for further translation, even though they would have worked in higher species, including humans.

We have previously demonstrated that the brain uptake of two PET tracers used for brain receptor imaging, $[^{11}\text{C}]$GR205171 and $[^{18}\text{F}]$Altanserin, was 3-6 fold lower in rats than in humans, which is unsatisfactorily low [10]. In the same study, the uptake of $[^{18}\text{F}]$altanserin in the minipig brain was 3.8-fold higher than in the rat brain, apparently due to a lower P-gp activity in pigs. Detecting brain uptake of this magnitude during initial evaluation of a tracer would warrant further translation to humans.

In this study, we investigate if rodents generally display higher efflux transporter activity than pigs by studying the brain uptake of eight structurally different PET tracers in both rodents and pigs. Furthermore, we propose an experimental design which accounts for elevated P-gp activity in rodents and facilitates the translation of tracers from rodents to higher species. Specifically, we supplement the traditional evaluation of tracer uptake at baseline and after selective target block with concomitant inhibition of P-gp activity.

Fig. 1 summarizes our set-up. In short, rats were scanned under four experimental conditions: drug-naïve or “baseline” (1), target block (2), P-gp inhibition (3) and target block combined with P-gp inhibition (4). The advantage of this set-up is that, in addition to assessing the specific binding of the tracer, it determines whether the tracer is a P-gp substrate or not. Importantly, this set-up is compatible with the higher-throughput scanning approach earlier reported by us [11], where four rats are scanned simultaneously in a clinical PET scanner. Thus, all four experimental conditions can be evaluated in a single scan.

Eight PET tracers for three different receptor systems were used in this study. Serotonin 5-HT$_{2A}$ receptor tracers $[^{18}\text{F}]$Altanserin, $[^{11}\text{C}]$Cimbi-36, $[^{11}\text{C}]$Pimavanserin and $[^{18}\text{F}]$MH.MZ, serotonin 5-HT$_{7}$ receptor tracers $[^{11}\text{C}]$Cimbi-701, $[^{11}\text{C}]$Cimbi-717 and $[^{11}\text{C}]$BA-10 and dopamine D$_{2/3}$ receptor tracer $[^{18}\text{F}]$Fallypride were studied.

Results of the tracer evaluation via both the traditional workflow (baseline and target block conditions) and the new workflow (P-gp inhibition alone and combined with target block) were used to predict the performance of the same tracer in pigs. The prediction algorithm is illustrated in Supplementary Fig. S1. We hypothesized that additional evaluation of a tracer’s P-gp dependency would give a better prediction of its performance in pigs and ultimately in humans than the traditional workflow.

**Methods**
Radiochemistry: $^{18}$FAltanserin, $^{11}$C CIMbi-36, $^{11}$C Pimavanserin, $^{18}$FMH.MZ, $^{18}$FFallypride, $^{11}$C CIMbi-701, $^{11}$C CIMbi-717 and $^{11}$C BA-10 were synthesized as previously reported [12–19]. Chemical structures of all compounds are displayed in the Electronic Supplementary Material (Supplementary Fig. S2).

Animals: 200-300 g (8-10 weeks) Long-Evans WT (or Sprague-Dawley in the case of Altanserin) female rats (Charles River, Calco, Italy) were housed in groups of 2-3 animals per cage in a climate-controlled rodent facility with a 12h light/dark cycle. The animals had free access to water and were fed ad libitum. All procedures were conducted in accordance with the European Commission's Directive 2010/63/EU, FELASA and ARRIVE guidelines for animal research and, with approval from The Danish Council for Animal Ethics (license numbers: 2017-15-0201-01283, 2012-15-2934-00156, 2007-561-1320) as well as the Department of Experimental Medicine, University of Copenhagen.

Pig PET experiments: Description of PET experiments in pigs and analysis of obtained data can be found in the Electronic Supplementary Material.

Rat PET scanning protocol: On the day of scanning, rats were transported to the scanner at least one hour prior to the experiment. Isoflurane, 3-3.5 % in 0.6% oxygen, was used to induce anaesthesia, while anaesthesia was maintained with 2.0-2.5 % isoflurane during the scans. The PET tracers were administered as intravenous (i.v.) bolus injections via tail vein catheters (BD Neoon 25G, Stockholm, Sweden) at the beginning of the scan with doses being between 5-20 MBq. The rats were subsequently scanned in the high-resolution research tomography (HRRT) scanner (Siemens AG, Munich, Germany) using a custom-made 2×2 rat holder, which enabled simultaneous scanning of four rats (Fig. 1) [11]. The animals were scanned for either 60 min ($^{11}$C) or 90 min ($^{18}$F), followed by a transmission scan at speed 10 (acquisition time approximately 6 min). The animals were scanned at baseline (no pre-treatment before tracer injection), and after receiving P-gp inhibition with or without target block. Details of inhibition and blocking regimens are described in Table 1. For combined inhibition and target block scans, rats were pre-treated with the P-gp inhibitor elacridar (5 mg/kg, Carbosynth, Compton, United Kingdom) and the 5-HT$_7$ antagonist SB-269970 (3 mg/kg, Tocris Bioscience, Abingdon, United Kingdom), the sigma and dopamine D$_{2/3}$ antagonist haloperidol (1 mg/kg, Janssen-Cilag, Birkerød, Denmark) or the 5-HT$_{2A}$ antagonist ketanserin (3 mg/kg, Sigma-Aldrich, Saint Louis, Missouri, USA). Elacridar was given 30 min prior to tracer injection through the intravenous catheter, and receptor blocking drugs were given 15 min before tracer injection. Chosen dosages and pre-treatment intervals were based on literature data [20–23].

Studies with $^{18}$FAltanserin were performed in a MicroPET Focus 120 scanner (Siemens Medical Solutions, Malvern, PA, USA). Hyponorm/midazolam (VetaPharma Ltd., Leeds, United Kingdom/Hameln Pharmaceuticals, Hameln, Germany) was used as anaesthesia. The rats received 11±2 MBq of the tracer as a bolus injection. Three of the rats were administered with 22.5 mg/kg bolus of Cyclosporin A (Sandimmun, Novartis, Basel, Switzerland) followed by a constant infusion of 7.5 mg/kg/h, starting 20-25 min before radiotracer administration, as previously described [10].
Rat PET image reconstruction: For HRRT scans (all tracers except $^{18}$FAltanserin), 60-minute list-mode PET data was transformed into 33 dynamic frames ($6 \times 10$, $6 \times 20$, $6 \times 60$, $8 \times 120$, and $7 \times 300$ seconds), while 90-minute list-mode PET data was transformed into 35 dynamic frames ($6 \times 10$, $8 \times 30$, $5 \times 60$, and $16 \times 300$ seconds). Attenuation maps were reconstructed from transmission scans using maximum a posteriori algorithm for transmission data (MAP-TR) with human head (HH) segmentation/thresholding scans [11]. All images were reconstructed using ordinary Poisson 3D ordered subset expectation maximization (OP-OSEM3D) algorithm with point spread function modelling. PET image frames consisted of 207 planes of $256 \times 256$ voxels of $1.22 \times 1.22 \times 1.22$ mm. $^{18}$FAltanserin scans were performed on the Focus 120 camera. 90-minute list-mode PET data was transformed into 25 dynamic frames ($10 \times 30$, $5 \times 120$, $5 \times 30$, and $5 \times 600$ seconds) and reconstructed using the filtered backprojection method. Reconstructed PET image frames consisted of 95 planes of $128 \times 128$ voxels of $0.87 \times 0.87 \times 0.80$ mm.

Table 1: Target blocking drugs, P-gp inhibitors and PET image summation timespan for rat PET experiments.

| Tracer       | Target blocking drug | Dose   | P-gp Inhibitor | Dose   | Time span for image summation |
|--------------|----------------------|--------|----------------|--------|------------------------------|
| $^{18}$FMH.MZ | ketanserin           | 3 mg/kg| elacridar      | 5 mg/kg| 5-90 min                     |
| $^{18}$FAltanserin | ketanserin     | 3 mg/kg| Cyclosporin A  | 22.5 mg/kg* | 5-90 min                     |
| $^{11}$CImavanserin | ketanserin    | 3 mg/kg| elacridar      | 5 mg/kg| 5-60 min                     |
| $^{11}$Cimbi-36 | ketanserin        | 3 mg/kg| elacridar      | 5 mg/kg| 5-60 min                     |
| $^{11}$Cimbi-717 | SB269970         | 3 mg/kg| elacridar      | 5 mg/kg| 2-60 min                     |
| $^{11}$Cimbi-701 | SB269970         | 3 mg/kg| elacridar      | 5 mg/kg| 2-60 min                     |
| $^{11}$CBA-10   | SB269970          | 3 mg/kg| elacridar      | 5 mg/kg| 30-60 min                    |
| $^{18}$FFallypride | haloperidol     | 1 mg/kg| elacridar      | 5 mg/kg| 5-90 min                     |

*After bolus injection of 22.5 mg/kg Cyclosporin A, rats received constant infusion of 7.5 mg/kg/h.

Quantification of rat PET data: For data analysis, the software PMOD 3.7 (PMOD Technologies, Zürich, Switzerland) was used. Summed PET images were generated based on all counts recorded in the time intervals specified in Table 1. Images were then aligned to a standardized MRI-based atlas of the rat brain [24] from where pre-defined regions of interest (ROIs) were extracted. Regions known to possess high...
densities of relevant receptors were selected as target ROIs: medial prefrontal cortex (mPFC) and frontal cortex (FC) for 5-HT$_{2A}$ receptor PET tracers [25], thalamus (Tha) for 5-HT$_7$ receptor PET tracers [16] and striatum (Str) for dopamine D$_{2/3}$ receptor tracer [26]. Cerebellum region (Cb), having low densities of receptors targeted by all investigated tracers, was chosen as a reference region (Supplementary Fig. S3). In addition, whole brain (Wb) ROI was chosen to monitor overall tracer penetration into the brain. The time-activity curves (TACs) for target ROIs were extracted from the PET images, and the activity was converted into standardized uptake values (SUV). SUV, expressed in g/mL, is equal to the concentration of radioactivity measured in the ROI divided by the injected radioactivity dose per body weight. Area under the curve (AUC) values were calculated from the TACs using GraphPad Prism 7 (GraphPad Software, California, USA) and expressed in min×g/mL. As scanning durations were different for $^{11}$C-labeled and $^{18}$F-labeled tracers (60 min and 90 min, respectively), AUC values of $^{18}$F-labeled tracers were calculated for both the full duration and the first 60 min of the scan.

**Rat data analysis:** Apparent target-specific binding of the tracers in the target regions was expressed as specific binding ratios (SBR), which were calculated from mean full scan length AUC values applying Equation 1; cerebellum was used as a reference region for all tracers. Changes in apparent specific binding of the tracers in response to target receptor blockade were calculated from SBR values using Equation 2; SBR changes were calculated for “baseline – target block” and “P-gp inhibition alone – combined P-gp inhibition and target block” condition pairs. Changes in tracer uptake in the target-rich region in response to P-gp inhibition were calculated from mean AUC values for the first 60 min of the scan as shown in Equation 3.

\[
SBR = \frac{AUC_{\text{target ROI}} - AUC_{\text{reference ROI}}}{AUC_{\text{reference ROI}}}
\]

\[
\%SBR\text{change} = 100\% \times \frac{SBR_{\text{baseline}} - SBR_{\text{block}}}{SBR_{\text{baseline}}}
\]

\[
\%AUC\text{change} = 100\% \times \frac{AUC_{60\min \text{ P-gp inhibition}} - AUC_{60\min \text{ baseline}}}{AUC_{60\min \text{ baseline}}}
\]

Evaluation of a tracer was considered successful if (whether with or without P-gp inhibition) the tracer showed an SBR value of at least 0.15 (15% higher uptake in the target region relative to reference region), and this SBR value decreased by at least 30% under target block condition.

**Results**

Of the four 5-HT$_{2A}$ receptor tracers investigated, only $[^{18}\text{F}]\text{MH.MZ}$ showed substantial uptake in the rat brain at baseline: AUC for the target receptor-rich mPFC was 60±5 min×g/mL (here and further AUC values refer to the first 60 min of the scan unless stated otherwise; full scan length AUC values for all tracers, ROIs and experimental conditions are presented in Supplementary Table S1; numbers of rats
scanned per experimental condition are shown in Supplementary Table S2). Baseline SBR for mPFC equalled 0.71. Pre-treatment with ketanserin, a 5-HT$_{2A}$ receptor antagonist, decreased SBR to 0.02 (–97% change). Under P-gp inhibition with elacridar, the AUC for the mPFC rose to 147 min×g/mL (+143%), and the SBR value for the mPFC reached 1.04. Combining target blockade with P-gp inhibition decreased the SBR to 0.04 (–96%). Thus, the 5-HT$_{2A}$ receptor-specific binding and the blocking of it were clearly detectable both with and without P-gp inhibition for [${}^{18}$F]MH.MZ (Fig. 2 and Supplementary Fig. S4).

In contrast, [${}^{18}$F]Altanserin, [${}^{11}$C]Pimavanserin and [${}^{11}$C]Cimbi-36 showed low brain penetration at baseline, with AUC values for mPFC (FC for [${}^{18}$F]Altanserin) in the range of 23-36 min×g/mL (Fig. 2 and Supplementary Fig. S4). SBR values were 0.33 for [${}^{18}$F]Altanserin, 0.02 for [${}^{11}$C]Pimavanserin and 0.18 for [${}^{11}$C]Cimbi-36. After ketanserin pre-treatment, [${}^{11}$C]Cimbi-36 SBR fell to 0.10 (–44%), while SBR values for [${}^{18}$F]Altanserin and [${}^{11}$C]Pimavanserin actually grew to 0.89 (+172%) and 0.04 (+110%), respectively. Thus, for these three tracers, blockable target-specific binding could only be detected for [${}^{11}$C]Cimbi-36.

After P-gp inhibition, mPFC AUC values for [${}^{18}$F]Altanserin, [${}^{11}$C]Pimavanserin and [${}^{11}$C]Cimbi-36 increased to 53 min×g/mL (+93%), 180 min×g/mL (+689%) and 174 min×g/mL (+391%), while SBR values reached 0.56, 0.03 and 0.65, respectively. Ketanserin blockade combined with P-gp inhibition resulted in SBR values of 0.32 (–42%) for [${}^{18}$F]Altanserin and 0.14 (–79%) for [${}^{11}$C]Cimbi-36. For [${}^{11}$C]Pimavanserin, AUC in the cerebellum after combined ketanserin and elacridar pre-treatment was greater than AUC in the mPFC, resulting in a negative SBR value of –0.10. However, a change in SBR from 0.03 to –0.10, although high in relative terms (–395%), can hardly be interpreted as a sign of target-specific binding because both values are very low.

All in all, for [${}^{18}$F]Altanserin, 5-HT$_{2A}$ receptor-specific binding and the blocking effect became observable after P-gp inhibition, for [${}^{11}$C]Cimbi-36 the use of P-gp inhibition led to an amplification of both apparent specific binding at baseline and the blocking effect, while [${}^{11}$C]Pimavanserin did not show any sign of specific 5-HT$_{2A}$ receptor binding either with or without P-gp inhibition (Fig. 2a).

AUC values reached 62 min×g/mL (+47%) for [${}^{11}$C]Cimbi-717, 142 min×g/mL (+277%) for [${}^{11}$C]Cimbi-701 and 65 min×g/mL (+121%) for [${}^{11}$C]BA-10 after P-gp inhibition with elacridar. Respective SBR values were 0.14, 0.18 and 0.16. Simultaneous inhibition of P-gp and blocking of the 5-HT$_{7}$ receptor decreased [${}^{11}$C]BA-10 SBR to 0.09 (–44%), while SBRs for [${}^{11}$C]Cimbi-717 and [${}^{11}$C]Cimbi-701 actually increased to 0.21 (+46%) and 0.22 (+23%), respectively. In summary, specific binding could only be detected for [${}^{11}$C]BA-10 after P-gp inhibition.

The dopamine D$_{2/3}$ receptor ligand [${}^{18}$F]Fallypride was included into the study as a non-serotonergic tracer. Baseline striatal AUC equalled 95 min×g/mL. Striatal SBR was 3.11 at baseline and fell to 0.01 (–100%) after haloperidol pre-treatment (Fig. 4 and Supplementary Fig. S5). After P-gp inhibition, striatal AUC rose to 244 min×g/mL (+158%), and SBR reached 4.07. Combined P-gp inhibition and target (D$_{2/3}$)
block decreased striatal SBR to 0.22 (~95%). Therefore, target-specific binding was clearly visible both without and with P-gp inhibition.

Evaluation of $[^{18}\text{F}]$MH.MZ, $[^{18}\text{F}]$Altanserin, $[^{11}\text{C}]$Pimavanserin, $[^{11}\text{C}]$Cimbi-36, $[^{11}\text{C}]$Cimbi-717 and $[^{11}\text{C}]$Cimbi-701 in pigs was reported previously [15,19,27,28]. Time-activity curves for $[^{11}\text{C}]$BA-10 and $[^{18}\text{F}]$Fallypride in pig brain are presented in Supplementary Fig. S6 and S7, respectively.

**Discussion**

In this work, we propose a higher-throughput approach to improve the translation of CNS PET tracers from rodents to higher species. Our data suggest that one of the main factors limiting translation of CNS tracers from rats to larger animals is the higher activity of efflux pumps, including P-gp, in rats. We used cyclosporine A and elacridar to inhibit the action of P-gp, the dominant drug efflux transporter in the rodent brain and study the influence of P-gp on the accumulation of a set of eight tracers [5].

Cyclosporine A is a selective P-gp inhibitor, while elacridar inhibits both P-gp and BCRP (breast cancer resistance protein) efflux pumps [29]. Within our data set, all investigated tracers showed higher brain uptake in rats when the action of P-gp was inhibited. The smallest increase in target-rich region AUC values after P-gp inhibition was observed for $[^{11}\text{C}]$Cimbi-717 (47%) and $[^{18}\text{F}]$Altanserin (93%), while for all other tracers, AUC values increased by 100-700%. Brain uptake of $[^{18}\text{F}]$Altanserin was previously reported to increase 2.6-fold (by 160%) in response to P-gp inhibition [10], which is comparable to the results obtained in this work using the same P-gp inhibition conditions. Higher increase reported in [10] could have been the consequence of a higher body weight of the rats used for the experiments (370 g vs 200-300 g in this work). It should be noted that all compounds evaluated by us are secondary and/or tertiary amines, which tend to be P-gp substrates [30,31]. However, an amino group is often present in CNS PET tracers.

In the absence of P-gp inhibition, only $[^{18}\text{F}]$MH.MZ, $[^{11}\text{C}]$Cimbi-36 and $[^{18}\text{F}]$Fallypride showed preferential accumulation (SBR values of >0.15) in target-rich regions and more than 30% reduction in SBR values after a selective target block (Fig. 2 and 4). $[^{18}\text{F}]$Altanserin demonstrated a decent SBR value (0.33) at baseline without P-gp inhibition, but ketanserin pre-treatment led to a drastic decrease of tracer uptake in both frontal cortex and cerebellum, with uptake in the cerebellum falling even more drastically (Supplementary Table S1). As a consequence, $[^{18}\text{F}]$Altanserin´s SBR after target blockade was higher compared to baseline conditions. Brain uptake in the reference ROI decreased more than in the target ROI in response to target blockade for $[^{11}\text{C}]$BA-10. These paradoxical observations may be explained by the hindered diffusion of the tracers across the BBB or their accelerated washout from the brain caused by the vasodilatory [20] or vasoconstrictory [32] properties of the respective blocking drugs (ketanserin and SB-269970). However, further research is required to unequivocally resolve this issue.

We hypothesized that the target binding of tracers that are actively transported out of the rat brain can nevertheless be assessed once the increased activity of efflux pumps is inhibited. Therefore, all eight
tracers were tested under P-gp inhibition with and without a simultaneous target block. P-gp inhibition led to an increase in baseline SBR values for all tracers (Supplementary Fig. S8). Five tracers ([18F]MH.MZ, [18F]Altanserin, [11C]Cimbi-36, [11C]BA-10, [18F]Fallypride) showed a pronounced reduction of apparent specific binding in target-rich regions (>30% SBR decrease) in response to target block under these conditions. These included [18F]Altanserin and [11C]BA-10, for which no such reduction could be demonstrated using the traditional workflow. For [11C]Pimavanserin, [11C]Cimbi-717 and [11C]Cimbi-701, no receptor-specific binding could be detected under P-gp inhibition: target region SBR values were either too low at baseline ([11C]Pimavanserin, Fig. 2) or failed to decrease after target receptor blockade ([11C]Cimbi-717 and [11C]Cimbi-701, Fig. 3). For the latter two tracers, their uptake in the target and reference ROIs under P-gp inhibition either did not change in response to target receptor blockade or slightly increased in both ROIs, which led to an increase in SBR (Fig. 3). This could have been caused by the perturbations in the cerebral blood flow due to the pharmacological action of the blocking drug (SB-269970, see above) or by the influx into the brain of the excess of the tracers displaced by from 5-HT7 receptors in peripheral tissues by the blocking drug.

Based on our data in rats, we predicted whether a tracer would work in pigs or not (see Supplementary Fig. S1), and compared these predictions to actual results obtained in pigs, as well as to the evaluation results in humans for those tracers that reached the clinical evaluation stage ([18F]MH.MZ, [18F]Altanserin, [11C]Cimbi-36 and [18F]Fallypride). Table 2 and Supplementary Table S3 summarize the outcomes. In contrast to rats (Fig. 2 and 3), low brain uptake was not an issue for any of the investigated tracers during evaluation in pigs and humans (Supplementary Table S3 and [33–36]). This confirms the notion that rats generally have a highly efficient brain efflux transporter system, which can limit the uptake of tracers in the brain, whereas in larger/higher species the efflux transporter system has less influence on the tracer uptake. Seven out of eight tracers displayed target-specific binding in pigs, i.e. pre-treatment with a specific receptor blocking agent reduced the displaceable distribution volume of the tracer in the target region (by 30% or more). For all tracers except [11C]Cimbi-701 and [11C]Cimbi-717, which had shown specific binding in pigs but not in rats, baseline BP_{ND} values in pigs highly correlated with baseline SBR values in rats, both with and without P-gp inhibition (Supplementary Fig. S9). [11C]Pimavanserin did not show any specific binding in pigs.

In our study, blocking experiments in rats without P-gp inhibition detected specific binding for three tracers ([18F]MH.MZ, [11C]Cimbi-36 and [18F]Fallypride) and without additional experiments in non-rodent species, the remaining tracers would likely have been discarded. The use of P-gp inhibition helped to additionally identify two tracers ([18F]Altanserin and [11C]BA-10) that showed specific binding. [11C]Pimavanserin did not show any specific binding either with or without P-gp inhibition in rats, and behaved in the same way in pigs. Agreement between pig and rat data on [11C]Pimavanserin is a positive finding within the framework of this study, even though it may be perceived as disappointing that a ligand with demonstrated sub-nanomolar affinity and high selectivity towards 5-HT2A receptors [37] turned out to be unsuitable for receptor imaging. Rodent data for [11C]Cimbi-701 and [11C]Cimbi-717, on the other
hand, demonstrates the limitations of brain radioligand evaluation in rodents: even with the use of P-gp inhibition, these tracers would have been discarded based on rodent data only. Apart from efflux transporter expression and activity, inter-species differences in receptor abundances or metabolic pathways are factors that may have a crucial impact on the translational validation of PET tracers [38,39]. Densities of 5-HT\textsubscript{2A}, 5-HT\textsubscript{7} and D\textsubscript{2/3} receptors in the respective receptor-rich regions of rodent, pig and human brain are summarized from literature data in Supplementary Table S4 [28,40–42]. Densities of 5-HT\textsubscript{7} receptors in rat and pig thalamus are very close, so the differences in metabolism between rats and pigs are a more likely explanation for the discrepancies observed in the results of [\textsuperscript{11}C]Cimbi-701 and [\textsuperscript{11}C]Cimbi-717 evaluation between these two species.

### Conclusions

The inclusion of P-gp inhibition into the workflow helped to predict the outcome of six out of eight cases (75% success rate), even though all tracers were strong substrates of P-gp. A traditional evaluation workflow without P-gp inhibition could only predict the outcome for four out of eight tracers (50% success rate). Our results demonstrate how addition of P-gp inhibition can aid to the interpretation of initial tracer evaluation in rats, improve the translatability and minimize unjustified discontinuations of promising tracers. We believe that the proposed workflow allows for a more effective initial \textit{in vivo} screening using rats.

### Declarations
Acknowledgements

The authors wish to thank the cyclotron staff at the Department of Clinical Physiology, Nuclear Medicine and PET, University Hospital Copenhagen, Rigshospitalet, Denmark, for radionuclide production and technical assistance.

Authors' contributions:

MMH, MP, GMK, SS and AK conceived and designed the study; ETL, FGE and VS developed and performed PET tracer synthesis; MX, ETL, VS, IVA, MP, NRS, SLB, HDH, LLD, AN and STP conducted animal experiments; MX, ETL, NRR, IVA, VS, MP, NRS and HDH analysed the results; MX, VS, MP, GMK, SS, ETL, MMH and NRR wrote or edited the manuscript. All authors read and approved the final version.

Funding:

This study was supported by funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813528 as well as from the Savværksejer Jeppe Juhls og Hustru Ovita Juhls foundation. Vladimir Shalgunov was supported by BRIDGE – Translational Excellence Programme (bridge.ku.dk) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation. Grant agreement no. NNF18SA0034956.

Conflicts of interest/Competing interests:

The authors have no conflicts of interest to disclose.

Availability of data and material:

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate:

All animal experiments were conducted in accordance with the European Commission’s Directive 2010/63/EU, FELASA and ARRIVE guidelines for animal research and with approval from The Danish Council for Animal Ethics (license numbers: 2017-15-0201-01283 and 2012-15-2934-00156) as well as the Department of Experimental Medicine, University of Copenhagen.

Consent for publication:

Not applicable.

Electronic Supplementary Material
Detailed overview of the experimental design, description of experiments in pigs, chemical structures of all studied compounds, investigated brain regions on the MRI template, time-activity curves for rat and pig ([18F]Fallypride and [11C]BA-10) scans, SBR and AUC values for all tracers, numbers of rats scanned per experimental condition are detailed in the Electronic Supplementary Material.

**Abbreviations**

5-HT<sub>2A</sub> – serotonin receptor of subtype 2A

5-HT<sub>7</sub> – serotonin receptor of subtype 7

ARRIVE - Animal Research: Reporting of In Vivo Experiments

ATP – adenosine triphosphate

AUC – area under the curve

BBB – blood-brain barrier

Cb – cerebellum

CNS – central nervous system

D<sub>2/3</sub> – dopamine receptors of subtypes 2 and 3

FC - frontal cortex

FELASA – Federation for Laboratory Animal Science Associations

HH – human head

HRRT – High Resolution Research Tomograph

MAP-TR - maximum a posteriori algorithm for transmission data

mPFC - medial prefrontal cortex

MRI – magnetic resonance imaging

OP-OSEM3D - ordinary Poisson 3D ordered subset expectation maximization

PET – positron emission tomography

P-gp – P-glycoprotein

ROI – region of interest
SBR – specific binding ratio

Str – striatum

TAC – time-activity curve

Tha – thalamus

Wb – whole brain

WT – wild-type

References

1. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. The Royal College of Radiologists; 2010;65:500–16.

2. Matthews PM, Rabiner EA, Passchier J, Gunn RN. Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol. 2012;73:175–86.

3. Comley J. In vivo preclinical imaging: An essential tool in translational research. Drug Discov. World. 2011. p. 58–71.

4. Ellenbroek B, Youn J. Rodent models in neuroscience research: is it a rat race? Dis Model Mech. 2016;9:1079–87.

5. Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol. 2013;9:237–52.

6. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117:333–45.

7. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591–602.

8. Schmitt U, Lee DE, Herth MM, Piel M, Buchholz H-G, Roesch F, et al. P-Glycoprotein Influence on the Brain Uptake of a 5-HT2A Ligand: [18F]MH.MZ. Neuropsychobiology. 2011;63:183–90.

9. Choi JY, Song JS, Lee M, Cho WK, Chung J, Lyoo CH, et al. P-Glycoprotein, not BCRP, Limits the Brain Uptake of [18F]Mefway in Rodent Brain. Mol Imaging Biol. 2016;18:267–73.

10. Syvänen S, Lindhe Ö, Palner M, Kornum BR, Rahman O, Långström B, et al. Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport. Drug Metab Dispos. 2009;37:635–43.

11. Keller SH, L'Estrade EN, Dall B, Palner M, Herth M. Quantification accuracy of a new HRRT high throughput rat hotel using transmission-based attenuation correction: A phantom study. 2016 IEEE Nucl Sci Symp Med Imaging Conf Room-Temperature Semicond Detect Work. IEEE; 2016. p. 1–3.
12. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med. Society of Nuclear Medicine; 1991;32:2266–72.

13. Mukherjee J, Yang Z-Y, Das MK, Brown T. Fluorinated benzamide neuroleptics—III. Development of (S)-N-[1-(allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol. 1995;22:283–96.

14. Herth MM, Debus F, Piel M, Palner M, Knudsen GM, Lüddens H, et al. Total synthesis and evaluation of [18F]MHMZ. Bioorganic Med Chem Lett. 2008;18:1515–9.

15. Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M, et al. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. Eur J Nucl Med Mol Imaging. Springer; 2011;38:681–93.

16. Hansen HD, Herth MM, Ettrup A, Andersen VL, Lehel S, Dyssegaard A, et al. Radiosynthesis and In Vivo Evaluation of Novel Radioligands for PET Imaging of Cerebral 5-HT7 Receptors. J Nucl Med. 2014;55:640–6.

17. Hansen HD, Lacivita E, Di Pilato P, Herth MM, Lehel S, Ettrup A, et al. Synthesis, radiolabeling and in vivo evaluation of [11C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyl)oxy)-2-propanol, a potential PET radioligand for the 5-HT7 receptor. Eur J Med Chem. Elsevier; 2014;79:152–63.

18. Herth M, Hansen H, Anders E, Lehel S, Kristensen J, Billard T, et al. Development of a novel 11C-labelled SB-269970 derivative for imaging the cerebral 5-HT7 receptors. J Nucl Med. Soc Nuclear Med; 2014;55:1814.

19. Andersen VL, Hansen HD, Herth MM, Dyssegaard A, Knudsen GM, Kristensen JL. 11C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. Bioorganic Med Chem Lett. 2015;25:1053–6.

20. van Nueten JM, Janssen PAJ, van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM. Vascular effects of Ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther. ASPET; 1981;218:217–30.

21. Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, et al. A Novel, Potent, and Selective 5-HT 7 Antagonist: (R)-3-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970). J Med Chem. 2000;43:342–5.

22. Burt DR, Creese I, Snyder SH. Properties of [3H] Haloperidol and [3H]Dopamine Binding Associated with Dopamine Receptors in Calf Brain Membranes. Mol Pharmacol. 1976;12:800–12.

23. Kallem R, P. Kulkarni C, Patel D, Thakur M, Sinz M, P. Singh S, et al. A Simplified Protocol Employing Elacridar in Rodents: A Screening Model in Drug Discovery to Assess P-gp Mediated Efflux at the Blood Brain Barrier. Drug Metab Lett. 2012;6:134–44.

24. Schiffer WK, Mirrione MM, Biegon A, Alexoff DL, Patel V, Dewey SL. Serial microPET measures of the metabolic reaction to a microdialysis probe implant. J Neurosci Methods. Elsevier; 2006;155:272–84.
25. Scott DO, Heath TG. Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat. J Pharm Biomed Anal. 1998;17:17–25.

26. Tantawy MN, Jones CK, Baldwin RM, Ansari MS, Conn PJ, Kessler RM, et al. [18F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. Nucl Med Biol. 2009;36:931–40.

27. L’Estrade ET, Shalgunov V, Edgar FG, Strebl-Bantillo MG, Xiong M, Crestey F, et al. Radiosynthesis and preclinical evaluation of [11 C]Cimbi-701 - Towards the imaging of cerebral 5-HT 7 receptors. J Label Compd Radiopharm. 2020;63:46–55.

28. Hansen HD, Ettrup A, Herth MM, Dyssegaard A, Ratner C, Gillings N, et al. Direct comparison of [18 F]MH.MZ and [18 F]altanserin for 5-HT 2A receptor imaging with PET. Synapse. Wiley Online Library; 2013;67:328–37.

29. Breedveld P, Beijnen JH, Schellens JHM. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci. 2006;27:17–24.

30. Ramu A, Ramu N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol. 1992;30:165–73.

31. Stouch TR, Gudmundsson O. Progress in understanding the structure–activity relationships of P-glycoprotein. Adv Drug Deliv Rev Elsevier; 2002;54:315–28.

32. Wang X, Fang Y, Liang J, Yan M, Hu R, Pan X. 5-HT7 Receptors Are Involved in Neurogenic Dural Vasodilatation in an Experimental Model of Migraine. J Mol Neurosci. 2014;54:164–70.

33. Kramer V, Dyssegaard A, Flores J, Soza-Ried C, Rösch F, Knudsen GM, et al. Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain. Eur J Nucl Med Mol Imaging. European Journal of Nuclear Medicine and Molecular Imaging; 2020;47:355–65.

34. Sadzot B, Lemaire C, Maquet P, Salmon E, Plenevaux A, Degueldre C, et al. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: Results in young normal controls. J Cereb Blood Flow Metab. 1995;15:787–97.

35. Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, et al. Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. J Cereb Blood Flow Metab. 2014;34:1188–96.

36. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, et al. Brain imaging of 18F-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. Wiley; 2002;46:170–88.

37. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropoxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine 2A Receptor Inverse Agonist. J Pharmacol Exp Ther. 2006;317:910–8.
38. Fowler JS, Ding YS, Logan J, Macgregor RR, Shea C, Garza V, et al. Species differences in [11C]clorgyline binding in brain. Nucl Med Biol. 2001;28:779–85.

39. Ma Y, Lang L, Kieselwetter D, Jagoda E, Eckelman WC. Species differences in metabolites of PET ligands: serotonergic 5-HT1A receptor antagonists 3-trans-FCWAY and 3-cis-FCWAY. Nucl Med Biol. 2006;33:1013–9.

40. Herth MM, Knudsen GM, Herth M. M. KGM. PET Imaging of the 5-HT2A Receptor System: A Tool to Study the Receptor's In Vivo Brain Function. In: Guiard B. DGG, editor. 5-HT2A Recept Cent Nerv Syst. Humana Press, Cham; 2018. p. 86–135.

41. L'Estrade ET, Erlandsson M, Edgar FG, Ohlsson T, Knudsen GM, Herth MM. Towards selective CNS PET imaging of the 5-HT7 receptor system: Past, present and future. Neuropharmacology. Elsevier; 2020;172:107830.

42. Cumming P. Absolute abundances and affinity states of dopamine receptors in mammalian brain: A review. Synapse. 2011;65:892–909.

**Figures**

| Step 1: Simultaneous PET scanning of four rodents | Step 2: PET Data Analysis | Step 3: Translation Prediction |
|------------------------------------------------|--------------------------|-------------------------------|
| ![Image](image-url) | ![Image](image-url) | ![Image](image-url) |

**Figure 1**

Tracer evaluation strategy. Step 1 and 2: Traditionally, specific binding can be determined by comparing tracer uptake at baseline and after target block (Case A). This work proposes to perform the same two experiments with simultaneous inhibition of P-gp (Case B). Step 3: If specific binding is observed in Case A or B, a successful translation from rodent to pig is predicted.
Figure 2

PET images (a), AUC and SBR values (b) for the 5-HT2A receptor tracers [18F]MH.MZ, [18F]Altanserin, [11C]Pimavanserin and [11C]Cimbi-36. Representative horizontal rat PET images, 60-min AUC values (min×g/mL) and SBR values are shown for baseline, target block with ketanserin, efflux transporter inhibition and combined P-gp inhibition - target block conditions (see Table 1 for details on drug dosing and PET image summation). n.d. = summed PET image could not be generated. Numbers of rats scanned per experimental condition are shown in Supplementary Table S2. Wb: whole brain, mPFC:
Figure 3

PET images (a), AUC and SBR values (b) for the 5-HT7 receptor tracers [11C]Cimbi-717, [11C]Cimbi-701, and [11C]BA-10. Representative horizontal rat PET images, 60-min AUC values (min×g/mL) and SBR values are shown for baseline, target block with SB-269970, P-gp inhibition with elacridar and combined P-gp inhibition - target block conditions (see Table 1 for details on drug dosing and PET image summation). Numbers of rats scanned per experimental condition are shown in Supplementary Table S2. Wb: whole brain, Tha: thalamus, Cb: cerebellum, AUC: area under the curve, SBR: specific binding ratios, P-gp: P-glycoprotein.
**Figure 4**

PET images, AUC and SBR values for the D2/3 receptor tracer [18F]Fallypride. Representative horizontal rat PET images, 60-min AUC values (min×g/mL) and SBR values are shown for baseline, target block with haloperidol, P-gp inhibition with elacridar and combined P-gp inhibition - target block conditions (see Table 1 for details on drug dosing and PET image summation, n = 2). Str: striatum, Cb: cerebellum, Wb: whole brain, AUC: area under the curve, SBR: specific binding ratios, P-gp: P-glycoprotein.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SI20200913PgpejnmmiresR1VS.docx